Literature DB >> 21765238

Is diffuse and peritumoral lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis?

D G P N Villagelin1, R B Santos, J H Romaldini.   

Abstract

BACKGROUND: Papillary thyroid carcinoma (PTC) is the most frequently diagnosed endocrine neoplasia, representing 70 to 80% of all diagnosed thyroid cancers. Furthermore, Hashimoto's thyroiditis is a frequent inflammatory thyroid disease and the main cause of hypothyroidism. The relationship between Hashimoto's thyroiditis and PTC remains controversial.
METHODS: Surgery for PTC was performed at our institution on 157 consecutive patients. They were classified by the degree of lymphocyte infiltration (LI). LI was classified as diffuse LI or peritumoral LI (only in or around the tumor), or absent. In addition, age, gender, tumor size, histopathological findings, lymph-node metastasis, extra- thyroidal extension, multifocal tumor, coexistence of LI and clinical outcomes were analyzed.
RESULTS: Out of the 141 patients included in the study, 83 (59%) had diffuse LI and 22 (16%) had peritumoral LI. In 36 patients (25%) LI was absent. A comparison of patients in the 3 groups revealed no significant difference in their genders, ages, smoking status, thyroid function, or nodule size at the time of surgery. The characteristics of PTC showed no differences in lymph-node metastasis, tumor invasion into contiguous neck structures, angioinvasion, or PTC subtypes. Tumor-node-metastasis (TNM) classification and classes did not differ among the 3 groups. During the follow-up, 64 out of 141 patients with PTC (55%) had recurrences from 6 to 130 months after the initial treatment. After a mean follow-up period of 8 yr we observed a significantly (p=0.01) high recurrence (66.6%) in the LI absent group with 24 of 36 patients when compared to patients from the diffuse LI group (32 out of 83 patients; 38.5%) and peritumoral LI group (8 out of 22 patients; 25%).
CONCLUSIONS: Although the role of the inflammatory-immune cells is complex and little understood, we found a more favorable course of PTC in the presence of LI (diffuse or peritumoral); this supports the hypothesis that LI represents a form of immune reaction to control tumor growth and proliferation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21765238     DOI: 10.3275/7870

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  54 in total

1.  Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland.

Authors:  M E DAILEY; S LINDSAY; R SKAHEN
Journal:  AMA Arch Surg       Date:  1955-02

2.  Proinflammatory mediators and genetic background in oncogene mediated tumor progression.

Authors:  John P Russell; Julie B Engiles; Jay L Rothstein
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

3.  RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response.

Authors:  E Puxeddu; J A Knauf; M A Sartor; N Mitsutake; E P Smith; M Medvedovic; C R Tomlinson; S Moretti; J A Fagin
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

4.  Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.

Authors:  B Belletti; P Ferraro; C Arra; G Baldassarre; P Bruni; S Staibano; G De Rosa; G Salvatore; A Fusco; M G Persico; G Viglietto
Journal:  Oncogene       Date:  1999-08-26       Impact factor: 9.867

5.  Pathologic features of Hashimoto's-associated papillary thyroid carcinomas.

Authors:  M Di Pasquale; J L Rothstein; J P Palazzo
Journal:  Hum Pathol       Date:  2001-01       Impact factor: 3.466

6.  Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells.

Authors:  Shogo Shinohara; Jay L Rothstein
Journal:  Oncogene       Date:  2004-09-30       Impact factor: 9.867

7.  Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans.

Authors:  I Okayasu; M Fujiwara; Y Hara; Y Tanaka; N R Rose
Journal:  Cancer       Date:  1995-12-01       Impact factor: 6.860

8.  High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.

Authors:  Gisele Oler; Janete M Cerutti
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

9.  Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma.

Authors:  Clara Ugolini; Fulvio Basolo; Agnese Proietti; Paolo Vitti; Rossella Elisei; Paolo Miccoli; Antonio Toniolo
Journal:  Thyroid       Date:  2007-05       Impact factor: 6.568

10.  The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.

Authors:  Hidetoshi Sumimoto; Fumie Imabayashi; Tomoko Iwata; Yutaka Kawakami
Journal:  J Exp Med       Date:  2006-06-26       Impact factor: 14.307

View more
  9 in total

1.  The role of tumor-infiltrating lymphocytes in papillary thyroid carcinomas.

Authors:  L L Cunha; F A Soares; J Vassallo; L S Ward
Journal:  J Endocrinol Invest       Date:  2011-10       Impact factor: 4.256

2.  Positive effect of RORγt on the prognosis of thyroid papillary carcinoma patients combined with Hashimoto's thyroiditis.

Authors:  Rong Zeng; Yi Lyu; Guoqiao Zhang; Tao Shou; Kai Wang; Heng Niu; Xinmin Yan
Journal:  Am J Transl Res       Date:  2018-10-15       Impact factor: 4.060

3.  Iodine, thyroid autoimmunity and cancer.

Authors:  Emilio Fiore; Francesco Latrofa; Paolo Vitti
Journal:  Eur Thyroid J       Date:  2015-03-03

Review 4.  Immune response in thyroid cancer: widening the boundaries.

Authors:  Laura Sterian Ward
Journal:  Scientifica (Cairo)       Date:  2014-09-25

5.  Is papillary thyroid microcarcinoma an indolent tumor?: A retrospective study on 280 cases treated with radioiodine.

Authors:  Xuemei Gao; Xiao Zhang; Yajing Zhang; Wenjuan Hua; Yusufu Maimaiti; Zairong Gao
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

6.  Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies.

Authors:  Shinje Moon; Hye Soo Chung; Jae Myung Yu; Hyung Joon Yoo; Jung Hwan Park; Dong Sun Kim; Young Joo Park
Journal:  Endocrinol Metab (Seoul)       Date:  2018-12

Review 7.  The Immune Landscape of Papillary Thyroid Cancer in the Context of Autoimmune Thyroiditis.

Authors:  Fabiana Pani; Paola Caria; Yoshinori Yasuda; Miyara Makoto; Stefano Mariotti; Laurence Leenhardt; Solmaz Roshanmehr; Patrizio Caturegli; Camille Buffet
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

8.  Thyroid antibody status exerts insignificant effect on lymph node metastasis of thyroid cancer.

Authors:  Youxing Zhou; Zhiqiang Sun; Yan Zhou; Cheng Tang; Xiaopeng Jiang; Fuliang Sun; Yi Ma; Jianfeng Cheng
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

9.  Bioinformatics analysis identified shared differentially expressed genes as potential biomarkers for Hashimoto's thyroiditis-related papillary thyroid cancer.

Authors:  Chang Liu; Yu Pan; Qinyu Li; Yifan Zhang
Journal:  Int J Med Sci       Date:  2021-08-13       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.